Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor ...Middle East

BEIJING, Aug. 2, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 in China. JAB-21822 is Jacobio's innovative in-house small molecule anti-cancer drug, which is designed to...

Hence then, the article about jacobio announces first patient dosed in phase i ii clinical trial of kras g12c inhibitor for solid tumor was published today ( Tuesday 03/08/2021 - 04:15 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor )

Also on site :

• Saudi Arabia to unify LPG gas cylinder prices nationwide from January 2026
• Two dozen killed in Ukrainian strike on Russian New Year’s celebration – governor
• Volunteer in Iran’s Revolutionary Guard reportedly killed during widening protests